JP2014062126A5 - - Google Patents

Download PDF

Info

Publication number
JP2014062126A5
JP2014062126A5 JP2014000383A JP2014000383A JP2014062126A5 JP 2014062126 A5 JP2014062126 A5 JP 2014062126A5 JP 2014000383 A JP2014000383 A JP 2014000383A JP 2014000383 A JP2014000383 A JP 2014000383A JP 2014062126 A5 JP2014062126 A5 JP 2014062126A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
propyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014000383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014062126A (ja
JP5955872B2 (ja
Filing date
Publication date
Priority claimed from EP05290727A external-priority patent/EP1707203A1/en
Application filed filed Critical
Publication of JP2014062126A publication Critical patent/JP2014062126A/ja
Publication of JP2014062126A5 publication Critical patent/JP2014062126A5/ja
Application granted granted Critical
Publication of JP5955872B2 publication Critical patent/JP5955872B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

JP2014000383A 2005-04-01 2014-01-06 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療 Active JP5955872B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05290727.6 2005-04-01
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06
US60/668,618 2005-04-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008503613A Division JP5546761B2 (ja) 2005-04-01 2006-03-30 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016045424A Division JP2016106142A (ja) 2005-04-01 2016-03-09 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療

Publications (3)

Publication Number Publication Date
JP2014062126A JP2014062126A (ja) 2014-04-10
JP2014062126A5 true JP2014062126A5 (enExample) 2016-04-28
JP5955872B2 JP5955872B2 (ja) 2016-07-20

Family

ID=35169680

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008503613A Active JP5546761B2 (ja) 2005-04-01 2006-03-30 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療
JP2014000383A Active JP5955872B2 (ja) 2005-04-01 2014-01-06 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療
JP2016045424A Pending JP2016106142A (ja) 2005-04-01 2016-03-09 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008503613A Active JP5546761B2 (ja) 2005-04-01 2006-03-30 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016045424A Pending JP2016106142A (ja) 2005-04-01 2016-03-09 非イミダゾールアルキルアミンヒスタミンh3−受容体リガンドによるパーキンソン病、閉塞性睡眠時無呼吸、レビー小体型認知症、血管性認知症の治療

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008016343A (es) 2006-06-23 2009-01-19 Abbott Lab Derivados ciclopropil amina como moduladores del receptro de histamina h3.
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
RS52626B (sr) 2006-07-25 2013-06-28 Cephalon Inc. Derivati piridizinona
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
CA2712897A1 (en) 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
MX377733B (es) * 2012-10-05 2025-03-11 Vtv Therapeutics Llc Tratamiento de enfermedad de alzheimer leve y moderada.
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
EP4688166A1 (en) 2023-03-31 2026-02-11 BIOPROJET Pharma Polymorph form of pitolisant hydrochloride
TW202535385A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽(pitolisant)之新穎調配物及使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
JPH07121938B2 (ja) 1991-12-18 1995-12-25 シェリング・コーポレーション 窒素含有6員複素環で置換されたイミダゾイルアルキル化合物
ES2090956T3 (es) 1991-12-18 1996-10-16 Schering Corp Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 H3−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
DE69432263T2 (de) 1993-11-15 2003-12-04 Schering Corp., Kenilworth Phenylalkyl-imidazole als h3-rezeptor-antagonisten
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
WO1996038142A1 (en) 1995-05-30 1996-12-05 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
WO1996040126A1 (en) 1995-06-07 1996-12-19 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
CA2244745A1 (en) 1996-02-09 1997-08-14 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
US6797726B1 (en) * 1999-06-11 2004-09-28 Toyama Chemical Co., Ltd. N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
GB9924941D0 (en) 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
PT1313721E (pt) * 2000-08-08 2006-06-30 Ortho Mcneil Pharm Inc Ariloxialquilaminas nao imidazoles como ligandos de receptor h3
EP1313470A4 (en) 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
WO2002015905A1 (en) * 2000-08-21 2002-02-28 Gliatech, Inc. The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
DE60224509T2 (de) * 2001-03-29 2009-03-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazolderivate verwendbar als histamin h3 rezeptorliganden
EP1451225A1 (en) * 2001-11-15 2004-09-01 Ortho-McNeil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
PT1451167E (pt) * 2001-12-10 2006-07-31 Ortho Mcneil Pharm Inc Fenilalcinos
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
WO2005007644A1 (ja) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体

Similar Documents

Publication Publication Date Title
JP2014062126A5 (enExample)
JP2016518337A5 (enExample)
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
JP2017537940A5 (enExample)
MX2015018032A (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
JP2017527578A5 (enExample)
JP2016514159A5 (enExample)
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
JP2014511892A5 (enExample)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2011037901A5 (enExample)
JP2017537954A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2023143940A5 (enExample)
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
JP2015510916A5 (enExample)
JP2016532632A5 (enExample)
JP2015537009A5 (enExample)
RU2016141650A (ru) Амидные соединения
JP2015516419A5 (enExample)
FI3248597T3 (fi) Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen
JP2016530238A5 (enExample)
JP2019151627A5 (enExample)